Showing results (1-10 of 179) with videos related to
Sort By:
Pageof 18
Breast Cancer Research : BCR|March 7, 2002
Cyclin D1 and mammary carcinoma: new insights from transgenic mouse modelsRobert L Sutherland, Elizabeth A MusgroveJournal of Mammary Gland Biology and Neoplasia|April 15, 2004
Cyclins and breast cancerRobert L Sutherland, Elizabeth A MusgroveBreast Cancer Research : BCR|January 14, 2010
CDK inhibitors as potential breast cancer therapeutics: new evidence for enhanced efficacy in ER+ diseaseRobert L Sutherland, Elizabeth A MusgroveNature Reviews. Cancer|August 25, 2009
Biological determinants of endocrine resistance in breast cancerElizabeth A Musgrove, Robert L SutherlandCritical Reviews in Oncogenesis|April 5, 2012
Inhibitors of cell cycle kinases: recent advances and future prospects as cancer therapeuticsAndrew Stone, Robert L Sutherland, Elizabeth A MusgroveBreast Cancer Research : BCR|November 6, 2007
Live or let die: oestrogen regulation of survival signalling in endocrine responseAlison J Butt, Robert L Sutherland, Elizabeth A MusgroveBMC Cancer|January 22, 2014
Targeting cyclin-dependent kinase 1 (CDK1) but not CDK4/6 or CDK2 is selectively lethal to MYC-dependent human breast cancer cellsJian Kang, C Marcelo Sergio, Robert L Sutherland, et al.Cancer Research|May 31, 2002
Mechanisms of growth arrest by c-myc antisense oligonucleotides in MCF-7 breast cancer cells: implications for the antiproliferative effects of antiestrogensJason S Carroll, Alexander Swarbrick, Elizabeth A Musgrove, et al.Endocrine-Related Cancer|August 23, 2005
Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin EAlison J Butt, Catriona M McNeil, Elizabeth A Musgrove, et al.Cell Cycle (Georgetown, Tex.)|January 18, 2013
Differences in degradation lead to asynchronous expression of cyclin E1 and cyclin E2 in cancer cellsC Elizabeth Caldon, C Marcelo Sergio, Robert L Sutherland, et al.Pageof 18